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Abstract
The major human apurinic/apyrimidinic endonuclease APE1 plays a pivotal role in the repair of base damage via
participation in the DNA base excision repair (BER) pathway. Increased activity of APE1, often observed in tumor cells, is
thought to contribute to resistance to various anticancer drugs, whereas down-regulation of APE1 sensitizes cells to DNA
damaging agents. Thus, inhibiting APE1 repair endonuclease function in cancer cells is considered a promising strategy to
overcome therapeutic agent resistance. Despite ongoing efforts, inhibitors of APE1 with adequate drug-like properties have
yet to be discovered. Using a kinetic fluorescence assay, we conducted a fully-automated high-throughput screen (HTS) of
the NIH Molecular Libraries Small Molecule Repository (MLSMR), as well as additional public collections, with each
compound tested as a 7-concentration series in a 4 mL reaction volume. Actives identified from the screen were subjected
to a panel of confirmatory and counterscreen tests. Several active molecules were identified that inhibited APE1 in two
independent assay formats and exhibited potentiation of the genotoxic effect of methyl methanesulfonate with a
concomitant increase in AP sites, a hallmark of intracellular APE1 inhibition; a number of these chemotypes could be good
starting points for further medicinal chemistry optimization. To our knowledge, this represents the largest-scale HTS to
identify inhibitors of APE1, and provides a key first step in the development of novel agents targeting BER for cancer
treatment.
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Introduction
The genome of mammalian cells is under constant threat from
both endogenous (namely reactive oxygen species, such as the
superoxide anion, hydroxyl radical, hydrogen peroxide, and
nitrogen-reactive species) and exogenous (e.g., sunlight, ionizing
radiation, chemical compounds and genotoxic drugs) DNA
damaging agents that can introduce mutagenic and cytotoxic
DNA lesions [1,2]. For example, it has been estimated that
spontaneous depurination events result in more than 10,000 abasic
lesions per mammalian cell per day [3,4]. Left unrepaired, DNA
damage can result in detrimental biological consequences to the
organism, including cell death and mutations that drive transfor-
mation to malignancy. Cells use various DNA repair systems as
defenses to protect their genomes from DNA damaging agents and
to maintain genome stability [5,6,7]. Not surprisingly, cells with a
defect in one of their DNA repair mechanisms are typically more
sensitive to certain genotoxic agents and suffer increased
mutagenesis.
Most antitumor drugs (e.g., alkylating, cross-linking and
intercalating agents, topoisomerase inhibitors, and certain anti-
metabolites) induce DNA lesions that ultimately block or interfere
with DNA replication in rapidly dividing cancer cells, resulting in
increased susceptibility to activation of various programmed cell
death responses [8]. An elevated DNA repair capacity in tumor
cells results in anticancer drug and radiation resistance, severely
limiting the efficacy of these agents. Recent basic and clinical
studies have demonstrated emerging concept designs to block the
functions of various proteins in specific DNA repair pathways,
which would sensitize cancer cells to DNA damaging agents and
potentially lead to an improved therapeutic outcome [9,10].
The base excision repair (BER) pathway is responsible for
correcting damage to single DNA bases or to the sugar moiety of
the phosphodiester backbone. Typically, the BER process starts
with the enzymatic removal of a damaged base by either a mono-
or a bi-functional DNA glycosylase, which creates an abasic (AP)
site or in some instances a DNA strand break. The AP site is
incised by an essential enzyme known as apurinic/apyrimidinic
endonuclease-1 (APE1) [11], which generates a single-stranded
gap in DNA with 39-hydroxyl and 59-deoxyribosephosphate
termini. This gap is filled in and ultimately sealed by the concerted
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action of DNA polymerases and ligases [4]. In mammalian cells,
APE1 is responsible for at least 95% of the endonuclease activity
that incises at abasic sites as part of the short-patch and long-patch
BER subpathways. APE1 has been found not only to be required
for animal viability, as deletion of both alleles of the APE1 gene in
mice leads to embryonic lethality, but also for cell viability in
culture [12,13].
Elevated levels of APE1 have been found in medulloblastoma
and primitive neuroectodermal tumors, prostate cancers, head-
and-neck cancers, non-small cell lung carcinomas, gliomas, and
osteosarcomas [4]. Over-expression of APE1 has been correlated
with increased cellular resistance to chemotherapeutic agents.
Moreover, APE1-deficient cells exhibit hypersensitivity to methyl
methanesulfonate (MMS), hydrogen peroxide, bleomycin, temo-
zolomide, gemcitabine, 1,3-bis (2-chloroethyl)-1-nitrosourea (a.k.a.
Carmustine), and the nucleoside analogue ß-L-dioxolane-cytidine
(a.k.a. Troxacitabine) [4,14]. Furthermore, the expression of a
dominant-negative APE1 protein (termed ED), which binds with
high affinity to substrate DNA and blocks subsequent repair steps
[15], augments the cell killing effect of 5-fluorouracil and 5-
fluorodeoxyuridine, implicating BER in the cellular response to
such anti-metabolites [16]. These data indicate that APE1 is an
attractive and rational target in the effort to improve therapeutic
efficacy of clinical DNA-interactive drugs through the inactivation
of the critical BER pathway.
A significant limitation of anti-cancer cytotoxins is their harmful
side-effects on normal tissue. While combinatorial treatment
strategies are still of interest, researchers and clinicians have been
pursuing the idea of synthetic lethality to reduce potential off-
target toxicities. In this scenario, inhibition of two independent
processes separately has little cellular consequence, whereas
inactivation of both pathways simultaneously leads to cell death.
This model has been exploited in the case of cancers deficient in
the breast cancer-related homologous repair proteins, BRCA1 and
BRCA2. Here, inhibitors against the poly(ADP-ribose) polymerase
protein, PARP-1, which operates in strand break responses,
including the single-strand break repair sub-pathway of BER, have
been shown to induce selective cell killing of BRCA-deficient cells
[8,17], presumably due to replication fork collapse and increased
genetic instability. Relevant to the effort within, inhibitors against
APE1 have been found to be synthetically lethal to cells deficient
in BRCA1 or BRCA2, or the checkpoint signaling protein ATM,
inducing accumulation of DNA double-strand breaks as well as
G2/M cell cycle arrest [18].
A number of chemical libraries have been screened to identify
small molecule inhibitors of APE1 endonuclease activity
[19,20,21,22,23]. Several molecules were identified from these
efforts, including 7-nitro-indole-2-carboxylic acid identified from a
screen of a 5000-compound collection [19]; several arylstibonic
acid derivatives identified from a screen of the National Cancer
Institute Diversity Set [20]; Reactive Blue 2, 6-hydroxy-DL-
DOPA, and myricetin, reported as prioritized hits from a screen of
the LOPAC1280 collection of bioactive compounds [21]; and 2,4,9-
trimethylbenzo [b] [1,8] naphthyridin-5-amine (dubbed AR03),
selected as the top hit from a 60,000-member library screen [23].
Additionally, an in-silico screen based on a pharmacophore
approach has led to the identification of several APE1 inhibitors
sharing a hydrophobic middle segment to which at least two
carboxyl substituents (or other negatively charged groups) are
attached via a range of linkers [22]; however, APE1 inhibition has
not been demonstrated for these compounds in cell-based models.
At present, none of the above compounds has been shown to have
clinical utility and, with very few exceptions, the inhibitors
reported to date are not readily amenable to further optimization
by medicinal chemistry due to multiple liabilities stemming from
their chemical structure [24].
We describe herein the first small molecule inhibitors of human
APE1 identified by quantitative high-throughput screening
(qHTS) [25] of a large public compound collection, the Molecular
Libraries Small Molecule Repository (MLSMR) of .300,000
compounds, as well as additional public libraries of the NIH
Chemical Genomics Center. Prioritized hits were further charac-
terized by a panel of biochemical assays and in MMS cell toxicity
potentiation models. Select compounds were also tested in an AP
site measurement assay designed to ascertain the inhibitors’ effect
on APE1 within a cellular context.
Materials and Methods
Reagents
Dimethyl sulfoxide (DMSO, certified ACS grade) was pur-
chased from Thermo Fisher Scientific. Tris-HCl, Thiazole Orange
(ThO), Tween-20, NaCl, and MgCl2 were obtained from Sigma,
while the arylstibonic control inhibitor NSC-13755 was supplied
by the National Cancer Institute Developmental Therapeutics
Program Repository.
The enzymes and substrates employed in this study (human
APE1 and E. coli Endo IV enzymes, fluorogenic and radioassay
substrates) were prepared and characterized as described previ-
ously [21]. The fluorescent probe employed in the fluorescence
polarization (FP) displacement assay was of the same composition
as the fluorogenic HTS substrate with the exception of the Black
Hole Quencher-2 moiety. The double-stranded 17-mer DNA
fragment used in the ThO DNA binding assay was of the same
sequence as the fluorogenic HTS substrate but carried no dye
labels.
Compound Library
The 352,498-member library comprised two main subsets: NIH
Molecular Libraries Small Molecule Repository (MLSMR),
prepared as 10 mM stock solutions in 384-well plates and
delivered by Biofocus DPI (South San Francisco, CA, http://
mli.nih.gov/mli/compound-repository/mlsmrcompounds/), and
NCGC internal exploratory collection, which consisted of several
commercially available libraries, as well as collections from
academic compound libraries. The compound library was sourced
as DMSO solutions at initial concentrations ranging between 2
and 10 mM and was further serially diluted for qHTS in 1536-well
format as described in detail elsewhere [26,27]. For follow-up
testing of primary screen actives, screening hits and their
analogues were sourced as powders from the respective original
suppliers (Sigma-Aldrich, NCI, Asinex, ChemBridge, Tocris,
Ambinter, and ChemDiv), dissolved in DMSO to produce
10 mM initial stock solutions, and serially diluted in twofold steps
for a total of 12 concentrations in duplicate. The identities of all
compounds screened are available in PubChem under Assay
Identifier 2517, http://pubchem.ncbi.nlm.nih.gov/.
High-throughput Screen
The screen was performed following the previously published
protocol [21]. All screening operations were performed on a fully
integrated robotic system (Kalypsys, San Diego, CA) [28] with
library plates screened proceeding from the lowest to the highest
concentration to minimize compound carryover [26]. Vehicle-
only plates, with DMSO being pin-transferred to the entire
column 5–48 compound area, were included regularly throughout
the screen in order to record any systematic shifts in assay signal.
Large-Scale Screen for APE1 Inhibitors
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During the screen, reagent bottles were kept at 4uC and all liquid
lines were covered with aluminum foil to minimize degradation.
Screening data were corrected and normalized, and concen-
tration–effect relationships was derived using in-house developed
algorithms [25]. Percent activity was computed after normaliza-
tion using the median values of the uninhibited enzyme control (32
wells located in column 1) and the no-enzyme, or 100% inhibited,
control (64 wells, entire columns 3 and 4), respectively, and
concentration-response data were fitted using a four parameter
Hill equation [29] by minimizing the residual error between the
modeled and observed responses. After curve fitting, active
compounds were analyzed based on their potency and concen-
tration-response curve characteristics, taking into consideration
the presence of asymptotes, efficacy of response, and confidence of
curve fit [25]. After preliminary clustering of actives based on
structural similarity analysis using Leadscope software (Leadscope
Inc., Columbus, OH) [30] selected hits were procured for re-
testing in the primary screening assay and potential follow-up
studies.
Figure 1. High-throughput screen. A) Assay principle. APE1 catalyzes and incision 59 relative to the abasic site analog (THF) to liberate a short 59-
fluorophore donor F-labeled deoxyoligonucleotide, causing increased fluorescence signal. F represents TAMRA fluorophore and Q represents Black
Hole Quencher 2. The APE1 incision site is indicated by the arrow. B) High-speed data collection allows monitoring of the reaction progress in kinetic
mode as shown in the main panel (3 data points collected over the course of 2 min, shown for 7 wells representing the serial dilution of library
compound MLS000090966); the changes in fluorescence signal for each well over the two-minute period are normalized against no-enzyme and no-
inhibitor controls to produce the concentration response curve for the sample as shown in the inset. C) A stable Z’ screening factor was maintained
throughout the screen. D) A dilution series of the previously reported arylstibonic acid inhibitor NSC-13755 applied to every assay plate yielded a
near-constant IC50 of 35 nM.
doi:10.1371/journal.pone.0047974.g001
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ThO DNA Displacement and E. coli Endo IV Profiling
Assays
In order to screen out nonselective compounds, such as non-
specific DNA binders and inhibitors of related enzymes, we used a
miniaturized ThO DNA displacement assay and a counterscreen
against the bacterial endonuclease E. coli Endo IV, respectively,
following the previously published protocols [21].
Fluorescence Polarization (FP) Displacement Assay
Double-stranded oligodeoxynucleotide containing tetrahydro-
furan (THF) abasic site labeled with TAMRA at the 59-end was
used as the labeled binding probe. Inhibition of APE1 binding to
labeled probe was detected by a decrease in the fluorescence
polarization (FP) of the fluorophore. Briefly, 4 mL mixture of
20 nM APE1 and 5 nM probe contained in the enzymatic assay
buffer from which Mg2+ was omitted, was dispensed into 1536-
Figure 2. Representative curves observed from 10 screening hits chosen to demonstrate the range of potencies observed in the
concentration-response-based screen. Structures and additional data associated with these hits are presented within Figure 7.
doi:10.1371/journal.pone.0047974.g002
Figure 3. Hit progression flow chart.
doi:10.1371/journal.pone.0047974.g003
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PLOS ONE | www.plosone.org 4 October 2012 | Volume 7 | Issue 10 | e47974
well Greiner black solid bottom plates. Compounds (23 nL) were
transferred via pintool, and after a 15-minute incubation at room
temperature, fluorescence polarization was measured in a View-
Lux High-throughput CCD imager (480 nm excitation and
540 nm emission) to determine the degree of probe displacement
caused by the test compounds.
Gel-based APE1 Assays
To test the compounds’ inhibitory activity after the primary
screen, two assays designed to monitor the cleavage of substrate to
product through electrophoretic separation were utilized. The
radiotracer incision assay, utilizing a 32P-labeled substrate, was
performed essentially as described [21,31,32]. Incision reactions
utilizing 32P-labeled substrate were carried out for 5 min at 37uC.
After the addition of an equal volume of stop buffer (0.05%
bromophenol blue and xylene cyanol, 20 mM EDTA, 95%
formamide), the substrate and product were separated on a
standard polyacrylamide denaturing gel and quantified by
PhosphorImager analysis [32]. The fluorescence-based assay
utilized a 59-TAMRA labeled 32-mer oligonucleotide containing
a THF moiety at position 18 (59-TAMRA-
TTTTTTTTTTTTTCACCFTCGTACGACTCCGT-39) an-
nealed with a complementary 20-mer oligonucleotide (59-ACG-
GAGTCGTACGAGGGTGA-39) was used in this assay. APE1
cleavage of the substrate results in a 18-mer TAMRA-labeled
fragment which was separated by a non-denaturing polyacryl-
amide gel electrophoresis and quantitated in a Gel Doc XR
imaging system, BioRad (Hercules, CA). The advantage of this
assay is that it can be used in a relatively high throughput mode
with the inhibitors tested at a range of concentrations (0.17 mM to
125 mM was used here). APE1 (0.15 nM) was added to a reaction
mixture of 20 mL containing assay buffer (40 mM HEPES pH 7.5,
50 mM NaCl, 1 mM MgCl2 and 2 mM DTT), and labeled ds
DNA substrate (final 75 nM). The mixture was incubated at RT
for 15 min, and the reaction was stopped by the addition 20 mL of
2X dye stop solution (10% glycerol, 20 mM EDTA and
bromophenol blue). Then 10 mL of the mixture was resolved on
20% polyacrylamide gel in 1X Tris-borate EDTA running buffer
at 250 V for 40 min.
MMS Potentiation Assay
HeLa cells were plated at 6000 cells/well in DMEM culture
medium containing 10% FBS into white solid bottom 384-well cell
culture plates. The plates were incubated at 37uC overnight for
cell attachment, followed by media replacement. The fresh
medium contained serial dilutions of compounds of interest in
the presence (0.4 mM final) or absence of MMS. The plates were
incubated for 24 h at 37uC. Cell viability was determined by
luminescence detection after an addition of 15 mL of CellTiter Glo
reagent (Promega, Madison, WI). Percent viability was calculated
for each concentration of compound tested in duplicate by relating
the corresponding luminescence to that of a negative DMSO
vehicle control. MMS potentiation trends were defined as follows:
negative (-), if cell viability in the compound-plus-MMS treatment
was the same as that of the DMSO-plus-MMS control (overlap-
ping dose-response curves); inconclusive (I), if the shift in the cell
viability dose-response upon MMS inclusion relative to com-
pound-alone was less than 30%; and positive (P), if the difference
between the compound-plus-MMS and compound-alone curves
was at least 30%, and maintained within at least a two-fold
compound concentration span.
AP Site Measurement
HeLa cells at 80% confluency (66105 cells) were subjected to
the following treatments in a 6-well plate for 24 hours at 37uC: 1)
DMSO alone, 2) 275 mM MMS, 3) APE1 inhibitors dissolved in
DMSO (5–20 mM final compound concentration), and 4) the
inhibitors as in treatment 3 in combination with 275 mM MMS.
Cells were then harvested and processed using a Qiagen Genomic
DNA isolation kit (Germantown, MD). After DNA quantitation,
AP sites were measured using the DNA Damage Quantification kit
from Dojindo Molecular Technologies (Rockville, MD).
Results and Discussion
Quantitative High-throughput Screen
To screen for inhibitors of APE1 incision activity, we employed
a purified-enzyme biochemical assay with a model substrate
featuring a red-shifted fluorescent reporter in combination with a
dark non-emitting quencher. These moieties were incorporated as
end labels onto a 17-mer double-stranded DNA fragment
containing a centrally-located tetrahydrofuran AP site sugar
mimetic, which serves as the APE1 cleavage site. Upon APE1-
catalyzed strand scission immediately 59 to the AP site analog, the
shortened oligodeoxynucleotide carrying the fluorescent reporter
spontaneously dissociates from the rest of the substrate, leading to
an increase in fluorescence due to its spatial separation from the
Figure 4. Elimination of assay artifacts and promiscuous hits. A)
An autofluorescent compound contributes fluorescence intensity well
in excess of the assay reaction’s average leading to the computation of
aberrant concentration response curve. B) An example of a promiscu-
ous hit acting by strong DNA binding as evidenced by the highly similar
concentration responses observed in the primary screen (empty
squares) and the ThO counterscreen (filled squares).
doi:10.1371/journal.pone.0047974.g004
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dark quencher (Figure 1A). Further details on the generation and
validation of this substrate in fully-integrated robotic miniaturized
assays have been reported elsewhere [21]. Prior to the full-
collection screen, the assay was tested and found to perform
reproducibly by screening the LOPAC1280 library of pharmaco-
logically active compounds in triplicate using a fully-integrated
robotic system (data not shown).
The assay was applied to screen a diverse 352,498-compound
library that contained the National Institutes of Health public
collection, the MLSMR. The compounds tested were arrayed as
seven-point titrations, at final concentrations of 57 mM, 11.4 mM,
2.3 mM, 457 nM, 91 nM, 18 nM, and to 3.7 nM. Using a high-
speed whole-plate fluorescence imager, the assay data for the
entire screen was conducted in kinetic mode, with the APE1
incision reaction being monitored over the initial linear time frame
of 2 min (Figure 1B). Thus, any inhibition associated with each
sample was computed from the alteration in fluorescence intensity
over the time-course measurement period, after normalization
against the appropriate controls (Figure 1B, inset). The assay
performed well during the entire course of the screen: the Z’
statistical factor remained consistent without fluctuation, at an
average of 0.79 (the maximum Z’ factor possible is 1.0, with values
of greater than 0.5 being considered an indication of a highly
stable screening assay) [33] (Figure 1C). In addition, the intra-plate
control titration of the arylstibonic inhibitor NSC-13755 [20]
yielded a near-constant concentration-response curve with an
average IC50 of 35 nM and a minimum significant ratio of 1.9 (the
best possible ratio is 1.0, while ratios of less than 4 are generally
Figure 5. Significant potentiation of the genotoxic effect of MMS by 12 prioritized hits (designated P in Table S1). HeLa cells were
exposed to a dilution series of each compound shown in the absence (empty squares) and presence of 400 mM MMS (filled squares), and after a 24-
hour incubation the cell viability was measured by ATP-content detection using CellTiter Glo. Results are presented as averages and standard
deviations from duplicate samples, normalized against control.
doi:10.1371/journal.pone.0047974.g005
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indicative of an assay with high test-to-test reproducibility of dose
responses) [27,34] (Figure 1D).
Unlike traditional HTS, qHTS provides a concentration
response curve (CRC) for each compound and allows for
calculation of an IC50 value for each compound in the primary
screen. Approximately 1,100 compounds with full concentration-
response curves and IC50 values of less than 30 mM were
identified, and similarity analysis of the hits led to 121 clusters
and 154 singletons, representing a wide variety of structural classes
(the qHTS results are available in PubChem under Assay
Identifier 2517, http://pubchem.ncbi.nlm.nih.gov/). Representa-
tive concentration-response curves from 8 hits spanning most of
the potency range (double-digit nanomolar to double-digit
micromolar IC50) are shown in Figure 2. The progression of hits
through the respective steps of cheminformatics analysis, confir-
matory testing, and additional profiling, is depicted as a flow chart
in Figure 3.
After exclusion of heavy metal- and reactive functionality-
containing molecules, and after using the real-time kinetic
screening data to flag compounds that interfere with the assay
signal by contributing excessive amounts of fluorescence [35] (an
example of a highly fluorescent hit, the bioactive fluorescent sensor
calcein NCGC00094849, is shown in Figure 4A), 745 hits were
selected for further characterization based on potencies and
concentration-response curve quality. Of the 745 cherry-picked
compounds, 595 (80%) exhibited activity upon retesting using the
original fluorogenic screening assay.
Follow-up Testing of Primary Screening Hits
To eliminate false positive hits, all 595 confirmed molecules
were tested for their ability to inhibit APE1 incision activity using
biochemical assays that involve electrophoretic separation of the
substrate and cleavage product. We adopted a two-step approach:
(1) hits possessing complete screen-derived concentration response
curves were tested at a single concentration in the low-throughput
electrophoretic separation assay with radiolabel detection and (2)
lower confidence hits possessing either incomplete or noisy
concentration response curves were tested as a seven-point dilution
series using a higher-throughput electrophoretic separation assay
with fluorescence detection. Of the 391 compounds tested in the
Figure 6. Modest potentiation of the genotoxic effect of MMS exhibited by 16 prioritized hits (designated I in Table S1). HeLa cells
were exposed to a dilution series of each compound shown in the absence (empty squares) and presence of 400 mM MMS (filled squares), and after a
24-hour incubation the cell viability was measured by ATP-content detection using CellTiter Glo. Results are presented as averages and standard
deviations from duplicate samples, normalized against vehicle control.
doi:10.1371/journal.pone.0047974.g006
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radioassay, 112 displayed at least 50% inhibition of APE1 activity
at 100 mM. Given that the radioassay was specifically conducted at
a substrate conversion rate approaching 100%, the fact that a
majority of the HTS hits (namely, the weakest and most
nonspecific) failed to pass this rigorous APE1 inhibition criterion
was not unexpected. Of the 204 compounds tested in the
fluorescence-based gel assay, 111 displayed reproducible dose-
dependent inhibition. A total of 223 positive compounds showing
activity in these electrophoretic separation based assays were then
subjected to a panel of assays in order to further assess their
engagement with the APE1 target in vitro, as well as to evaluate
their selectivity. The complete set of results obtained for these 223
compounds in the below tests is provided within Table S1.
To detect screening hits that inhibit APE1 activity through non-
specific DNA interactions, we employed a previously established
miniaturized ThO dye displacement assay [21]. Forty-three
compounds were active in the DNA-binding counter-screen; the
majority of these compounds were weak DNA binders (Table S1).
Most of the DNA binders possessed the typical chemical features
associated with DNA binding: (i) extended conjugated unsaturated
ring systems, which would allow them to intercalate between the
stacked bases, and/or (ii) accumulation of positively-charged
nitrogens, which would permit nonspecific electrostatic interac-
tions with DNA. Of note, classic DNA binders, such as
daunorubicin- and tetracycline-like compounds (for example
NCGC00093976, NCGC00024246, and NCGC00163605, Table
S1), exhibited a strong dose-dependent fluorescence signal increase
due to their autofluorescent properties, which interfered with the
ThO signal and produced distorted dose-response curves. One of
the most potent DNA binders among the tested HTS hits was
phthalocyanine tetrasulfonate hydrate (NCGC00165867), with a
ThO dye displacement IC50 of 0.631 mM, which is a very similar
potency to that seen in the primary screening assay (Figure 4B).
We note that the ThO assay reports primarily on DNA binders
acting through intercalation, while potentially missing other types
of DNA binders, such as those acting through the minor groove.
However, promiscuous DNA binders which may have been missed
by the ThO assay are likely to be flagged during the next profiling
step, i.e. the test for inhibition of E. coli EndoIV, described below.
To probe the selectivity of the candidate APE1 inhibitors, we
tested them against E. coli EndoIV [36], employing the same assay
as used in the HTS. E. coli EndoIV, while exhibiting similar
biochemical activities to APE1, such as AP site incision, has no
sequence or structural homology to human APE1 [37], and thus
serves as a tool for identifying broad-acting endonuclease
inhibitors. Twenty-one compounds yielded full or partial concen-
tration response curves against EndoIV (Table S1). Of these 21
compounds, 15 were already revealed as DNA binders by the
ThO assay, and thus, were anticipated to represent non-specific
inhibitors. Of the EndoIV-positive hits, only six (compounds
NCGC00024246, NCGC00094813, NCGC00159344,
NCGC00161415, NCGC00165867, NCGC00166058, Table S1)
possessed complete concentration response curves for EndoIV,
and the IC50 values of these compounds were significantly higher
than the corresponding APE1 potencies. These results indicate
that the majority of qHTS-output compounds more selectively
inhibit APE1 than EndoIV, and the six compounds above
represent potential starting points for the design of EndoIV-
specific inhibitors.
To gain insight into the mode of action of the hits, we employed
a displacement assay combined with fluorescence polarization (FP)
detection to test the small molecule’s effect on the binding of APE1
to a version of the fluorogenic AP site-containing oligonucleotide
substrate that was devoid of the quencher functionality. FP is a
Figure 7. Screening hits showing significant activity in the MMS cytotoxicity enhancement experiments. qHTS, IC50 (mM) obtained in
the initial quantitative high-throughput screen; Gel, percent incision observed in the presence of 100 mM compound using the radiotracer detection
or estimated IC50 value (mM) using the fluorescence detection; FP, IC50 (mM) or annotation of response (N.A., no activity observed; P.C., partial
concentration response curve) obtained in the fluorescence polarization displacement assay; MMS, potentiation of the genotoxic effect of
methylmethane sulfonate (P, positive).
doi:10.1371/journal.pone.0047974.g007
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convenient technique for providing a basic characterization of
macromolecular associations, such as protein-DNA [38] and
protein-protein interactions [39]. Following incubation of the
compound, APE1, and DNA substrate together, inhibition of
APE1 binding to AP-DNA would be revealed as a decrease in FP
of the fluorophore. The assay, which is performed in the absence
of magnesium to prevent enzymatic turnover, is target DNA-
specific, as APE1 binds with higher affinity to duplex DNA
containing an AP site than to an undamaged counterpart [36]. Of
the 223 hits validated in the electrophoretic separation assays, 70
compounds showed a concentration-dependent decrease in FP in
the displacement assay, indicating an inhibition of APE1 AP-DNA
binding. These results provide an early indication with respect to
the mechanism of action of each compound, although the
sensitivity of the displacement assay is lower than that of the
enzymatic assay, making it difficult to reveal relevant, but weak,
protein binders.
Potentiation of the Genotoxic Effect of MMS in HeLa Cells
To examine the biological prospects of the top compounds, we
tested their ability to inhibit APE1 DNA repair activity by
assessing enhancement of MMS toxicity in mammalian cells.
Figure 8. AP-site accumulation. HeLa cells were exposed to each compound shown in the absence and presence of 275 mM MMS, and total
genomic AP sites were measured as described in Methods. The number of AP sites per 106 base pairs of genomic DNA are presented as the average
and standard deviation of two independent measurements. P-values (*P,0.05, **P,0.01) were calculated to evaluate the significance of the
enhancement of AP site levels produced by the combined treatment versus MMS alone. N.S., not significant (P$0.05); P-value designations for
MLS000587064 and MLS000115025 shown in parentheses are derived from the repeat testing reported in Figure S1.
doi:10.1371/journal.pone.0047974.g008
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MMS creates methylated-base damage to genomic DNA, which,
when excised by an alkylpurine DNA glycosylase, results in a high
number of cytotoxic AP sites [40]. We compared the viability of
HeLa cells exposed to a dilution series of inhibitor alone to a
combination of a fixed MMS concentration with the same dilution
series of inhibitor by using a standard CellTiter Glo luminescence
assay. This technique measures the number of viable cells in
culture based on quantitation of the ATP present, which signals
the presence of metabolically active cells. The assay was further
optimized for 384-well plates, allowing a high-throughput testing
of multiple hits at multiple concentrations, a scope of investigation
previously impossible due to the very low throughput of the
traditionally applied colony formation assay.
From the 223 compounds found positive in the gel-based APE1
assays, exclusion of the most promiscuous hits, that is, those that
were both DNA binders and EndoIV-inhibitory, yielded a set of
170 compounds (Figure 3). This shortened group of hits was tested
in the cell-based potentiation assay for their ability to dose-
dependently enhance sensitivity of HeLa cells to the alkylating
agent MMS. Of the 170 compounds tested, 12 enhanced the
cytotoxicity of MMS significantly (the difference between the
compound-plus-MMS and compound-alone responses was at least
30% and was maintained within at least a two-fold compound
concentration range, Figure 5), while 16 compounds produced a
modest response (the separation between the curves was greater
than the errors of measurement but was less than 30% viability at
any given compound concentration, Figure 6). The structures and
assay data associated with the 12 compounds that exhibited
significant effect in the MMS potentiation assay are presented in
Figure 7.
AP Site Accumulation
As stated above, the application of the genotoxic agent MMS
results in an increase in the level of AP sites within the genome. An
effective APE1-targeted inhibitor applied under the conditions of
increased genotoxic stress is expected to interfere with the repair of
AP sites, while ideally having no effect on the AP site levels when
applied as a single agent. Thus, the net effect of treating cells with
a combination of MMS and inhibitor would be an increase in the
number of AP site lesions. To determine the effect on AP site
accumulation caused by treatment with MMS in combination with
an APE1 inhibitor, as compared to treatment with MMS or
inhibitor alone, we measured AP site levels in the chromosomal
DNA from HeLa cells using an aldehyde-reactive probe-based
colorimetric assay [40]. The concentrations of MMS and inhibitor
(275 mM for MMS and between 5 and 30 mM for the inhibitor,
respectively) were selected to fall below the onset of cytotoxicity for
each agent based on the analysis of the MMS potentiation data
shown in Figure 5.
Of the 12 compounds that significantly enhanced the cytotox-
icity of MMS (Figure 3), 11 were tested in the AP site
accumulation experiments (MLS001217741 was not tested due
to resupply shortage). These experiments revealed that in general
the number of AP sites was only slightly increased in the cells
exposed to the compounds alone relative to the vehicle control, but
was significantly increased when cells were exposed to both MMS
and most of the tested compounds (Figure 8). The exceptions to
this trend were inhibitors where a noticeable increase in AP sites
was observed upon treatment with the inhibitor alone
(MLS001306480 (P = 0.0198), MLS001196838 (P= 0.0238),
MLS001076862 (P = 0.0234)). Thus, compounds whose applica-
tion as single agents resulted in an increase inAP sites may be of
lesser utility as drug candidates, due to their potential to induce
genotoxic damage by themselves. Also, for several hits, the
combination treatment raised the level of AP sites very slightly
(relatively small standard deviations and no statistical significance
between AP site levels detected in combination treatments versus
MMS-alone: MLS000737267, MLS000863573, MLS000594187,
MLS001076862) or the increase in AP site levels with the
combined treatment was obscured by large standard deviations
observed in the combination experimental group
(MLS000587064, MLS000090966, and MLS000115025). In an
attempt to provide further support for the preliminary trends, we
ran additional AP-site measurement experiments on the three hits
(MLS000587064, MLS000090966, and MLS000115025) which
produced the large error bars seen in the ‘‘Combined’’ treatment
category (Figure 8): the repeat tests produced smaller standard
deviations and appear to support the initially-observed enhance-
ments for MLS000587064 and MLS000115025 (Figure S1). We
note that because the AP site experiments are laborious in nature,
and consistent with the need to provide initial profiling on a
relatively large number of screening hits, the number of replicates
incorporated in this experiment (two), as well as the combinations
of inhibitor and MMS concentrations, were insufficient for a
complete statistical analysis of the trends. In order for a true
Combination Index to be derived [41], which in turn would allow
for a definitive conclusion to be draw regarding the potential
synergistic nature of the inhibitor effect on the MMS genotoxicity,
a large matrix of inhibitor and MMS concentrations needs to be
tested, making it impossible to provide such an exhaustive
characterization for all top hits reported here. We further note
that given the laborious nature of the AP site experiments, we have
limited this initial study to only the 24-hour treatment condition:
the longer-term effect (.3 days of treatment) of APE1 inhibitors
on AP site accumulation is an important factor to consider during
the development of one or more of the hits, particularly given the
previously-highlighted vital role of APE1 as a resolver of abasic
DNA damage accrued through natural causes [12].
With the exception of MLS001306480, an antimalarial
pyronaridine used primarily in China [42], which is a quina-
crine-like molecule that bears distant resemblance to the
previously published APE1 inhibitors lucanthone [43], mitoxan-
throne [21], and Reactive Blue 2 [21], none of the hit compounds
that caused an increase in AP sites in cells under genotoxic stress
were similar to previously reported APE1 inhibitors, including
AR03 [23] or the pharmacophore model advanced by Zawahir
and colleagues [22]. This overall result provides a support to the
notion that screening of additional libraries to find novel APE1
inhibitory scaffolds is indeed a viable approach.
Of the top hits, substituted isoxazole alkylamines like
MLS001105846 have been patented as agri-horticultural fungi-
cides [44]. Although outside this current profiling work, the
MLS001105846 compound does not appear to have been tested in
conjunction with human disease applications. MLS000419194
possesses no obvious liabilities and was recently taken through a
medicinal chemistry optimization campaign by us [45].
The remaining hits that potentiate the MMS response and
cause AP site accumulation belong to structural classes typically
associated with promiscuity (that is, prone to bind to multiple
protein targets in the cell) or carry potentially reactive or labile
functional groups. The flavonoid derivative MLS000737267, also
known as galloflavin (a product derived from gallic acid oxidation),
has been shown to inhibit human immunodeficiency virus
integrase at a low-micromolar IC50 [46]. Phenanthrenes derived
from orchid plant species, bearing similar chemical features to the
trimethoxyphenanthrene-diol hit MLS000863573, have recently
been highlighted for their anti-inflammatory activity, presumably
by inhibiting the lipopolysacharide-induced nitric oxide produc-
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tion in murine macrophages [47]. Both MLS000737267 and
MLS000863573 are undesirable from the standpoint of further
medicinal chemistry optimization because of the polyphenolic
nature. MLS000594187, which bears a resemblance to the above
two hits, in that it has a core consisting of three fused 6-membered
rings in a phenanthrene-like configuration, belongs to a different
chemical class, benzo(c)chromen-6-ones, which has been advanced
as selective estrogen receptor b modulators [48]. MLS001196838
was recently characterized as a potent and selective inhibitor of the
histone acetyltransferase (HAT) p300, and has been employed to
probe HAT’s role in acute myelogenous leukemia [49,50]. A
derivative of MLS001076862 has been reported as a modulator of
the survival protein MCL-1, and displays cellular activity and thus
potential utility for treating hyperproliferative, inflammatory, and
other disorders [51]. Of note, MLS001196838 and
MLS001076862 contain an exocyclic enone functionality, which
may be reactive and would need to be modified prior to an
extended optimization of these scaffolds. The pyrimidine-2,4,6-
trione central core unit within MLS000587064 derives from
barbituric acid, although this compound itself does not belong to
the group of typical barbiturates. Most recently, pyrimidine-2,4,6-
trione derivatives were shown to be highly effective in a protein
aggregation protection assay model of amyotrophic lateral sclerosis
and to possess good bioavailability [52]. Lastly, the furanyl-
tetrahydromethyl-indole MLS000090966 was recently reported to
be an effective inhibitor of tubulin assembly [53]. MLS000587064
and MLS000090966 contain a catechol diether moiety, a
recognized chemical liability [54].
Taken together, our analyses have revealed a promising set of
structurally diverse heretofore unreported APE1 inhibitors. As
with all typical high-throughput screening and follow-up cam-
paigns, it is plausible that additional APE1-inhibitory chemotypes
of drug-like characteristics, which reside in our collection, may
have been missed due to the application of the series of stringent
selection criteria in order to narrow down the list of hits being
followed up. At present, it is hoped that the public availability of all
screening and secondary assay data will lead to further exploration
of this information-rich resource.
Supporting Information
Figure S1 Repeat AP site testing of the three hits whose
combination treatments produced large standard deviations
(MLS000587064, MLS000090966, and MLS000115025 in
Figure 8) upon initial testing. A decrease in the standard deviation
was observed for these compounds upon repeat testing, with
significant difference (*P,0.05, **P,0.01) between the combina-
tion and MMS-alone treatments obtained for MLS000587064 and
MLS000115025, confirming the initially-observed enhancement
trends.
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Table S1 HTS hits which displayed inhibition in the electro-
phoretic separation based assays.
(DOCX)
Acknowledgments
We thank Sam Michael for assistance with the robotic screening and
Rajarshi Guha for help with the statistical analyses.
Author Contributions
Conceived and designed the experiments: DD DK VNV DJM AJ DMW
AS. Performed the experiments: DD DK VNV. Analyzed the data: DD
DK VNV DJM AJ DMW AS. Contributed reagents/materials/analysis
tools: DD DK VNV DJM AJ DMW AS. Wrote the paper: DD DK VNV
DJM AJ DMW AS.
References
1. Bapat A, Fishel M, Kelley MR (2009) Going Ape as an Approach to Cancer
Therapeutics. Antioxid Redox Signal 11: 651–668.
2. Kulkarni A, Wilson DM, 3rd (2008) The involvement of DNA-damage and -
repair defects in neurological dysfunction. Am J Hum Genet 82: 539–566.
3. Fortini P, Pascucci B, Parlanti E, D’Errico M, Simonelli V, et al. (2003) The base
excision repair: mechanisms and its relevance for cancer susceptibility.
Biochimie 85: 1053–1071.
4. Abbotts R, Madhusudan S (2010) Human AP endonuclease 1 (APE1): from
mechanistic insights to druggable target in cancer. Cancer Treat Rev 36: 425–
435.
5. Barnes DE, Lindahl T (2004) Repair and genetic consequences of endogenous
DNA base damage in mammalian cells. Annu Rev Genet 38: 445–476.
6. Karran P, Offman J, Bignami M (2003) Human mismatch repair, drug-induced
DNA damage, and secondary cancer. Biochimie 85: 1149–1160.
7. Cleaver JE (2005) Cancer in xeroderma pigmentosum and related disorders of
DNA repair. Nat Rev Cancer 5: 564–573.
8. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA
repair pathways as targets for cancer therapy. Nat Rev Cancer 8: 193–204.
9. Powell SN, Bindra RS (2009) Targeting the DNA damage response for cancer
therapy. DNA Repair (Amst) 8: 1153–1165.
10. Sharma RA, Dianov GL (2007) Targeting base excision repair to improve
cancer therapies. Mol Aspects Med 28: 345–374.
11. Wilson DM, 3rd, Barsky D (2001) The major human abasic endonuclease:
formation, consequences and repair of abasic lesions in DNA. Mutat Res 485:
283–307.
12. Fung H, Demple B (2005) A vital role for Ape1/Ref1 protein in repairing
spontaneous DNA damage in human cells. Mol Cell 17: 463–470.
13. Izumi T, Brown DB, Naidu CV, Bhakat KK, Macinnes MA, et al. (2005) Two
essential but distinct functions of the mammalian abasic endonuclease. Proc Natl
Acad Sci U S A 102: 5739–5743.
14. Fishel ML, Kelley MR (2007) The DNA base excision repair protein Ape1/Ref-
1 as a therapeutic and chemopreventive target. Mol Aspects Med 28: 375–395.
15. McNeill DR, Wilson DM, 3rd (2007) A dominant-negative form of the major
human abasic endonuclease enhances cellular sensitivity to laboratory and
clinical DNA-damaging agents. Mol Cancer Res 5: 61–70.
16. McNeill DR, Lam W, DeWeese TL, Cheng YC, Wilson DM, 3rd (2009)
Impairment of APE1 function enhances cellular sensitivity to clinically relevant
alkylators and antimetabolites. Mol Cancer Res 7: 897–906.
17. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose
polymerase inhibitors for the treatment of cancers deficient in DNA double-
strand break repair. J Clin Oncol 26: 3785–3790.
18. Sultana R, McNeill DR, Abbotts R, Mohammed MZ, Zdzienicka MZ, et al.
(2012) Synthetic lethal targeting of DNA double-strand break repair deficient
cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer in
press: n/a-n/a.
19. Madhusudan S, Smart F, Shrimpton P, Parsons JL, Gardiner L, et al. (2005)
Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic
Acids Res 33: 4711–4724.
20. Seiple LA, Cardellina JH, 2nd, Akee R, Stivers JT (2008) Potent inhibition of
human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids. Mol
Pharmacol 73: 669–677.
21. Simeonov A, Kulkarni A, Dorjsuren D, Jadhav A, Shen M, et al. (2009)
Identification and characterization of inhibitors of human apurinic/apyrimidinic
endonuclease APE1. PLoS ONE 4: e5740.
22. Zawahir Z, Dayam R, Deng J, Pereira C, Neamati N (2009) Pharmacophore
guided discovery of small-molecule human apurinic/apyrimidinic endonuclease
1 inhibitors. J Med Chem 52: 20–32.
23. Bapat A, Glass LS, Luo M, Fishel ML, Long EC, et al. (2010) Novel small
molecule inhibitor of Ape1 endonuclease blocks proliferation and reduces
viability of glioblastoma cells. J Pharmacol Exp Ther 334: 988–998.
24. Wilson III DM, Simeonov A (2010) Small molecule inhibitors of DNA repair
nuclease activities of APE1. Cell Mol Life Sci 67: 3621–3631.
25. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, et al. (2006)
Quantitative high-throughput screening: a titration-based approach that
efficiently identifies biological activities in large chemical libraries. Proc Natl
Acad Sci U S A 103: 11473–11478.
26. Yasgar A, Shinn P, Jadhav A, Auld D, Michael S, et al. (2008) Compound
Management for Quantitative High-Throughput Screening. JALA Charlottesv
Va 13: 79–89.
27. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, et al. (2007) High-
throughput screening assays for the identification of chemical probes. Nat Chem
Biol 3: 466–479.
Large-Scale Screen for APE1 Inhibitors
PLOS ONE | www.plosone.org 11 October 2012 | Volume 7 | Issue 10 | e47974
28. Michael S, Auld D, Klumpp C, Jadhav A, Zheng W, et al. (2008) A robotic
platform for quantitative high-throughput screening. Assay Drug Dev Technol
6: 637–657.
29. Hill AV (1910) The possible effects of the aggregation of the molecule of
haemoglobin on its dissociation curves. J Physiol(London). 4–7.
30. Roberts G, Myatt GJ, Johnson WP, Cross KP, Blower PE, Jr. (2000) LeadScope:
software for exploring large sets of screening data. J Chem Inf Comput Sci 40:
1302–1314.
31. Wilson DM, 3rd, Takeshita M, Grollman AP, Demple B (1995) Incision activity
of human apurinic endonuclease (Ape) at abasic site analogs in DNA. J Biol
Chem 270: 16002–16007.
32. Wilson DM, 3rd (2005) Ape1 abasic endonuclease activity is regulated by
magnesium and potassium concentrations and is robust on alternative DNA
structures. J Mol Biol 345: 1003–1014.
33. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for
Use in Evaluation and Validation of High Throughput Screening Assays.
J Biomol Screen 4: 67–73.
34. Eastwood BJ, Farmen MW, Iversen PW, Craft TJ, Smallwood JK, et al. (2006)
The Minimum Significant Ratio: A Statistical Parameter to Characterize the
Reproducibility of Potency Estimates from Concentration-Response Assays and
Estimation by Replicate-Experiment Studies. J Biomol Screen 11: 253–261.
35. Jadhav A, Ferreira R, Klumpp C, Mott BT, Austin C, et al. (2010) Quantitative
Analyses of Aggregation, Autofluorescence, and Reactivity Artifacts in a Screen
for Inhibitors of a Thiol Protease J Med Chem 53: 37–51.
36. Erzberger JP, Barsky D, Scharer OD, Colvin ME, Wilson DM, 3rd (1998)
Elements in abasic site recognition by the major human and Escherichia coli
apurinic/apyrimidinic endonucleases. Nucl Acids Res 26: 2771–2778.
37. Mol CD, Hosfield DJ, Tainer JA (2000) Abasic site recognition by two apurinic/
apyrimidinic endonuclease families in DNA base excision repair: the 3’ ends
justify the means. Mutat Res 460: 211–229.
38. Heyduk T, Heyduk E (2002) Molecular beacons for detecting DNA binding
proteins. Nat Biotechnol 20: 171–176.
39. Lea WL, Simeonov A (2011) Fluorescence Polarization Assays in Small
Molecule Screening. Expert Op Drug Disc 6: 17–32.
40. Wyatt MD, Pittman DL (2006) Methylating agents and DNA repair responses:
Methylated bases and sources of strand breaks. Chem Res Toxicol 19: 1580–
1594.
41. Chou T-C (2006) Theoretical Basis, Experimental Design, and Computerized
Simulation of Synergism and Antagonism in Drug Combination Studies.
Pharmacological Reviews 58: 621–681.
42. Auparakkitanon S, Chapoomram S, Kuaha K, Chirachariyavej T, Wilairat P
(2006) Targeting of hematin by the antimalarial pyronaridine. Antimicrob
Agents Chemother 50: 2197–2200.
43. Naidu MD, Agarwal R, Pena LA, Cunha L, Mezei M, et al. (2011) Lucanthone
and Its Derivative Hycanthone Inhibit Apurinic Endonuclease-1 (APE1) by
Direct Protein Binding. PLoS ONE 6: e23679.
44. Shimozono N, Wada H, Biotech S (2004) Substituted Isoxazole Alkylamine
Derivative and Agri- and Horticultural Fungicide. WO/2003/074501.
45. Rai G, Vyjayanti VN, Dorjsuren D, Simeonov A, Jadhav A, et al. (2012)
Synthesis, Biological Evaluation, and Structure-Activity Relationships of a Novel
Class of Apurinic/Apyrimidinic Endonuclease 1 Inhibitors. J Med Chem 55:
3101–3112.
46. Hong H, Neamati N, Winslow HE, Christensen JL, Orr A, et al. (1998)
Identification of HIV-1 integrase inhibitors based on a four-point pharmaco-
phore. Antivir Chem Chemother 9: 461–472.
47. Hwang JS, Lee SA, Hong SS, Han XH, Lee C, et al. (2010) Phenanthrenes from
Dendrobium nobile and their inhibition of the LPS-induced production of nitric
oxide in macrophage RAW 264.7 cells. Bioorg Med Chem Lett 20: 3785–3787.
48. Sun W, Cama LD, Birzin ET, Warrier S, Locco L, et al. (2006) 6H-
Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med
Chem Lett 16: 1468–1472.
49. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, et al. (2010) Virtual ligand
screening of the p300/CBP histone acetyltransferase: identification of a selective
small molecule inhibitor. Chem Biol 17: 471–482.
50. Wang L, Gural A, Sun XJ, Zhao X, Perna F, et al. (2011) The leukemogenicity
of AML1-ETO is dependent on site-specific lysine acetylation. Science 333:
765–769.
51. Walensky LD, Stewart ML, Cohen N, Institute D-FCR (2011) Small Molecules
for the Modulation of MCL-1 and Methods for Modulating Cell Death, Cell
Division, Cell Differentiation, and Methods of Treating Disorders. WPO, WO/
2011/094708.
52. Xia G, Benmohamed R, Kim J, Arvanites AC, Morimoto RI, et al. (2011)
Pyrimidine-2,4,6-trione Derivatives and Their Inhibition of Mutant SOD1-
Dependent Protein Aggregation. Toward a Treatment for Amyotrophic Lateral
Sclerosis. J Med Chem 54: 2409–2421.
53. Screpanti E, Santaguida S, Nguyen T, Silvestri R, Gussio R, et al. (2010) A
Screen for Kinetochore-Microtubule Interaction Inhibitors Identifies Novel
Antitubulin Compounds. PLoS ONE 5: e11603.
54. Rishton GM (1997) Reactive compounds and in vitro false positives in HTS.
Drug Discovery Today 2: 382–384.
Large-Scale Screen for APE1 Inhibitors
PLOS ONE | www.plosone.org 12 October 2012 | Volume 7 | Issue 10 | e47974
